BioCentury | Jun 27, 2020
Product Development

BARDA no longer funding immunomodulators as support for the therapeutic class to treat COVID-19 grows

A slew of therapies entered the clinic this week aimed at tamping down the immune system to treat excessive lung inflammation in COVID-19 patients, even as BARDA announced it would no longer fund the class...
BioCentury | Jun 29, 2019

Biotech backs down in 2Q19

In a reversal from 1Q19, biotech stocks across all market cap tiers fell in the second quarter, leading to a total loss of $22.3 billion. However, the year-to-date change in market cap remains well in...
BioCentury | Jun 21, 2019
Company News

June 21 Company Quick Takes: FDA rejects Daiichi's AML candidate; plus Sanofi, Novartis and more

Complete response letter for Daiichi's quizartinib Daiichi Sankyo Co. Ltd. (Tokyo:4568) said FDA issued a complete response letter for quizartinib, its candidate to treat relapsed/refractory FLT3-ITD-positive acute myelogenous leukemia (AML). In May, an FDA advisory...
BioCentury | Apr 6, 2019

Big caps under pressure

Biogen’s fall in the wake of its decision to discontinue late-stage trials of Alzheimer’s therapy aducanumab is yet another reminder that large caps are in dire need of new pipeline products, and could serve as...
BioCentury | Jan 5, 2019

Ready to launch

The proposed $74 billion takeout of Celgene Corp. by Bristol-Myers Squibb Co. will not shift buysider attention away from upcoming and maturing drug launches heading into 2019, with plenty to track following a record year...
BioCentury | Dec 12, 2018
Preclinical News

Repurposing hypertension drugs to block cytokine release syndrome

Johns Hopkins University School of Medicine researchers showed that hypertension drug Demser metyrosine and an endogenous peptide in testing for hypertension could prevent cytokine release syndrome, a toxicity associated with immunotherapies, without compromising efficacy. Cytokine...
BioCentury | Jan 6, 2018

Burgeoning bellwethers

The miserable performance of large cap biotechs last quarter is likely to be a boon for small- and mid-cap players this year, in more ways than one. Buysiders spent most of 2017 focusing to a...
BioCentury | Sep 8, 2017
Company News

Fosun gains rights to bremelanotide in China and Taiwan from Palatin

Palatin Technologies Inc. (NYSE-M:PTN) granted Shanghai Fosun Pharmaceutical Group Co. Ltd. (Shanghai:600196; HKSE:2196) exclusive rights to develop and commercialize bremelanotide in China, including Hong Kong and Macau, and Taiwan to treat hypoactive sexual desire disorder...
BioCentury | Jan 20, 2017
Company News

Palatin, AMAG deal

Palatin granted AMAG exclusive, North American rights to develop and commercialize Rekynda bremelanotide. Palatin will receive $60 million up front and is eligible for up to $80 million in regulatory milestones and up to $300...
BioCentury | Jan 14, 2017

JPM jump

Nine of the 160 biotechs that presented at the 2017 JPMorgan Healthcare Conference not only skated through the volatile week unharmed, but managed to post gains of at least 15%, with Ariad Pharmaceuticals Inc. (NASDAQ:ARIA)...
Items per page:
1 - 10 of 213